These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

524 related items for PubMed ID: 27494299

  • 21. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Merkel M, Danese D, Chen C, Wang J, Wu A, Yang H, Lin H.
    Expert Opin Pharmacother; 2023; 24(10):1205-1214. PubMed ID: 37219406
    [Abstract] [Full Text] [Related]

  • 22. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
    Maurer MS, Grogan DR, Judge DP, Mundayat R, Packman J, Lombardo I, Quyyumi AA, Aarts J, Falk RH.
    Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
    [Abstract] [Full Text] [Related]

  • 23. Cutaneous biomarkers of therapeutic efficacy in early treatment of hereditary ATTR amyloid polyneuropathy with tafamidis.
    Cárdenas-Soto K, Dominguez XH, Cortes G, Tsai F, Saniger MDM, Guraieb-Chahin P, Torres-Ocatvo B, Gibbons C, Kelly JW, Freeman R, González-Duarte A.
    J Peripher Nerv Syst; 2024 Jun; 29(2):221-231. PubMed ID: 38706223
    [Abstract] [Full Text] [Related]

  • 24. Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5 Years.
    Merlini G, Coelho T, Waddington Cruz M, Li H, Stewart M, Ebede B.
    Neurol Ther; 2020 Jun; 9(1):105-115. PubMed ID: 32107748
    [Abstract] [Full Text] [Related]

  • 25. Tafamidis (Vyndaqel): a light for FAP patients.
    Nencetti S, Rossello A, Orlandini E.
    ChemMedChem; 2013 Oct; 8(10):1617-9. PubMed ID: 24000164
    [Abstract] [Full Text] [Related]

  • 26. Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis.
    Suhr OB, Conceição IM, Karayal ON, Mandel FS, Huertas PE, Ericzon BG.
    Neurol Ther; 2014 Dec; 3(2):101-12. PubMed ID: 26000226
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy.
    Shintani Y, Okada A, Morita Y, Hamatani Y, Amano M, Takahama H, Amaki M, Hasegawa T, Ohta-Ogo K, Kanzaki H, Ishibashi-Ueda H, Yasuda S, Shimazaki C, Yoshinaga T, Yazaki M, Sekijima Y, Izumi C.
    ESC Heart Fail; 2019 Feb; 6(1):232-236. PubMed ID: 30478886
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report.
    Fujita T, Inomata T, Kaida T, Iida Y, Ikeda Y, Nabeta T, Ishii S, Maekawa E, Naruke T, Koitabashi T, Kitamura E, Sekijima Y, Ako J.
    Cardiology; 2017 Feb; 137(2):74-77. PubMed ID: 28152524
    [Abstract] [Full Text] [Related]

  • 32. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis.
    Merlini G, Planté-Bordeneuve V, Judge DP, Schmidt H, Obici L, Perlini S, Packman J, Tripp T, Grogan DR.
    J Cardiovasc Transl Res; 2013 Dec; 6(6):1011-20. PubMed ID: 24101373
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Hereditary amyloidosis related to transthyretin V30M: disease progression in treated and untreated patients.
    Conceição I, Miranda B, Castro J, de Carvalho M.
    Eur J Neurol; 2018 Nov; 25(11):1320-e115. PubMed ID: 29924456
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies.
    Rozenbaum MH, Garcia A, Grima D, Tran D, Bhambri R, Stewart M, Li B, Heeg B, Postma M, Masri A.
    Eur Heart J Qual Care Clin Outcomes; 2022 Aug 17; 8(5):529-538. PubMed ID: 33895806
    [Abstract] [Full Text] [Related]

  • 37. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.
    Park J, Egolum U, Parker S, Andrews E, Ombengi D, Ling H.
    Ann Pharmacother; 2020 May 17; 54(5):470-477. PubMed ID: 31735059
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.